Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dose escalation and expansion of KER-047 in IRIDA
2021-000348-22Phase 2Terminated
- Sponsor
- Keros Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KER-047 in iron deficiency anemia (IDA), sponsored by Keros Therapeutics. Primary endpoint: Safety endpoints. Started Apr 2021; status: terminated.
02
Drugs
KER-047
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2021-000348-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000348-22.